Trial Profile
An open-label study evaluated the pharmacokinetics, safety and brain occupancy of ITI-007 in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Mar 2016
Price :
$35
*
At a glance
- Drugs Lumateperone (Primary)
- Indications Behavioural disorders; Mental disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Intra-Cellular Therapies
- 08 Mar 2016 New trial record